NO325119B1 - Brusk- og benmorfogenetisk reparasjonsmateriale, brusk- og benreparasjonsmiddel og anvendelser derav. - Google Patents
Brusk- og benmorfogenetisk reparasjonsmateriale, brusk- og benreparasjonsmiddel og anvendelser derav. Download PDFInfo
- Publication number
- NO325119B1 NO325119B1 NO19982236A NO982236A NO325119B1 NO 325119 B1 NO325119 B1 NO 325119B1 NO 19982236 A NO19982236 A NO 19982236A NO 982236 A NO982236 A NO 982236A NO 325119 B1 NO325119 B1 NO 325119B1
- Authority
- NO
- Norway
- Prior art keywords
- bone
- cartilage
- bone morphogenetic
- polyoxyethylene
- protein
- Prior art date
Links
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 title claims abstract description 56
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 title claims abstract description 56
- 210000000845 cartilage Anatomy 0.000 title claims abstract description 37
- 239000000463 material Substances 0.000 title claims abstract description 27
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 14
- 230000008439 repair process Effects 0.000 title claims description 26
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 44
- 229940112869 bone morphogenetic protein Drugs 0.000 claims abstract description 32
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims abstract description 32
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000007864 aqueous solution Substances 0.000 claims abstract description 12
- 229920001451 polypropylene glycol Polymers 0.000 claims abstract description 12
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims abstract description 10
- 208000010392 Bone Fractures Diseases 0.000 claims abstract description 6
- 230000007547 defect Effects 0.000 claims abstract description 3
- 101100472152 Trypanosoma brucei brucei (strain 927/4 GUTat10.1) REL1 gene Proteins 0.000 claims description 23
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 10
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 14
- 230000002441 reversible effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 230000001419 dependent effect Effects 0.000 abstract description 5
- 230000007704 transition Effects 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 25
- 229920001992 poloxamer 407 Polymers 0.000 description 23
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 150000002334 glycols Chemical class 0.000 description 11
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- 210000003000 inclusion body Anatomy 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 210000000689 upper leg Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 210000002805 bone matrix Anatomy 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000034127 bone morphogenesis Effects 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000001191 orthodromic effect Effects 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 238000011892 Von Kossa's method Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003459 anti-dromic effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000007355 cartilage morphogenesis Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- FGDZQCVHDSGLHJ-UHFFFAOYSA-M rubidium chloride Chemical compound [Cl-].[Rb+] FGDZQCVHDSGLHJ-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- -1 5 g/l Substances 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- 101100175316 Mus musculus Gdf5 gene Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002587 anti-hemolytic effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229940102127 rubidium chloride Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001256 stainless steel alloy Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000006277 sulfonation reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30756—Cartilage endoprostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/28—Bones
- A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2002/30001—Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
- A61F2002/30003—Material related properties of the prosthesis or of a coating on the prosthesis
- A61F2002/3006—Properties of materials and coating materials
- A61F2002/30062—(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7322402A JPH09143093A (ja) | 1995-11-17 | 1995-11-17 | 軟骨・骨誘導性修復用材料 |
| PCT/JP1996/003333 WO1997018829A1 (fr) | 1995-11-17 | 1996-11-14 | Materiaux inducteurs d'os/de cartilage en vue de leur reparation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO982236D0 NO982236D0 (no) | 1998-05-15 |
| NO982236L NO982236L (no) | 1998-06-26 |
| NO325119B1 true NO325119B1 (no) | 2008-02-04 |
Family
ID=18143268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19982236A NO325119B1 (no) | 1995-11-17 | 1998-05-15 | Brusk- og benmorfogenetisk reparasjonsmateriale, brusk- og benreparasjonsmiddel og anvendelser derav. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6903071B2 (ru) |
| EP (1) | EP0884052B1 (ru) |
| JP (1) | JPH09143093A (ru) |
| KR (1) | KR100458413B1 (ru) |
| CN (1) | CN1165340C (ru) |
| AT (1) | ATE254470T1 (ru) |
| AU (1) | AU712445C (ru) |
| CA (1) | CA2235400C (ru) |
| DE (1) | DE69630811T2 (ru) |
| DK (1) | DK0884052T3 (ru) |
| ES (1) | ES2211993T3 (ru) |
| HK (1) | HK1018205A1 (ru) |
| HU (1) | HU226201B1 (ru) |
| NO (1) | NO325119B1 (ru) |
| NZ (1) | NZ322188A (ru) |
| PT (1) | PT884052E (ru) |
| RU (1) | RU2180234C2 (ru) |
| UA (1) | UA63896C2 (ru) |
| WO (1) | WO1997018829A1 (ru) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09143093A (ja) * | 1995-11-17 | 1997-06-03 | Hoechst Japan Ltd | 軟骨・骨誘導性修復用材料 |
| EP2332564A1 (en) † | 1997-02-07 | 2011-06-15 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods thereof |
| US6309659B1 (en) | 1997-09-02 | 2001-10-30 | Gensci Orthobiologics, Inc. | Reverse phase connective tissue repair composition |
| AU1100101A (en) * | 1999-10-29 | 2001-05-14 | Children's Hospital Of Los Angeles | Bone hemostasis method and materials |
| US9616150B2 (en) | 1999-10-29 | 2017-04-11 | Children's Hospital Los Angeles | Bone hemostasis method and materials |
| DK1229940T3 (da) | 1999-11-15 | 2014-08-18 | Piramal Healthcare Canada Ltd | Temperaturstyret og ph-afhængig selvgelerende, vandig biopolymeropløsning |
| US7747332B2 (en) * | 2000-05-08 | 2010-06-29 | International Rehabilitative Sciences, Inc. | Electrical stimulation combined with a biologic to increase osteogenesis |
| EP1294414B1 (en) * | 2000-06-29 | 2006-03-15 | Biosyntech Canada Inc. | Composition and method for the repair and regeneration of cartilage and other tissues |
| JP2002306163A (ja) * | 2001-04-11 | 2002-10-22 | Chemo Sero Therapeut Res Inst | 大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法 |
| AU2002357898A1 (en) * | 2001-12-21 | 2003-07-15 | Gensci Orthobiologics, Inc. | End-capped polyalkylene glycols and compositions containing such compounds |
| US7205337B2 (en) * | 2001-12-21 | 2007-04-17 | Isotis Orthobiologics, Inc. | End-capped polymers and compositions containing such compounds |
| ES2633340T3 (es) * | 2002-05-20 | 2017-09-20 | Otsuka Pharmaceutical Co., Ltd. | Composición para reducir la opacidad de la piel |
| AU2002337479A1 (en) * | 2002-09-04 | 2004-03-29 | Hadasit Medical Research Services & Development Ltd. | Compositions comprising bone marrow cells, demineralized bone matrix and rtg polymers for use in the induction of bone and cartilage formation |
| EP1601326A4 (en) * | 2003-02-12 | 2011-05-11 | Ceremed Inc | RANDOM ALKYLENE OXIDE COPOLYMERS FOR MEDICAL AND SURGICAL USES |
| EP2001528A4 (en) * | 2006-03-23 | 2012-04-04 | Citagenix Inc | REVERSE-PHASE OSSEOCONDUCTIVE COMPOSITION |
| US20100047299A1 (en) * | 2007-01-25 | 2010-02-25 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Use of gdf-5 for the improvement or maintenance of dermal appearance |
| US8290780B2 (en) | 2009-06-24 | 2012-10-16 | International Business Machines Corporation | Dynamically extending the speech prompts of a multimodal application |
| KR101405104B1 (ko) * | 2011-12-26 | 2014-06-10 | 한남대학교 산학협력단 | 약물의 서방형 방출 특성을 가지는 골 시멘트 |
| US10743996B2 (en) * | 2017-03-24 | 2020-08-18 | Robert L. Bundy | Amnion putty for cartilage repair |
| CN109125791B (zh) * | 2018-09-29 | 2019-08-30 | 广州贝奥吉因生物科技有限公司 | 一种具有促进骨修复功能的可吸收骨蜡及制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61277612A (ja) * | 1985-05-31 | 1986-12-08 | Kiyoshi Morikawa | 接種用徐放性組成物 |
| JPH0723322B2 (ja) | 1985-12-07 | 1995-03-15 | 克之 藤井 | 液状骨形成剤からなる注射液 |
| NZ226171A (en) * | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
| US4863732A (en) * | 1987-12-16 | 1989-09-05 | Collagen Corporation | Injectable composition for inductive bone repair |
| US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
| JPH045227A (ja) * | 1990-04-17 | 1992-01-09 | Pharmetrix Corp | 歯周疾患治療システム |
| CA2040460C (en) * | 1990-05-01 | 1997-06-10 | Tacey X. Viegas | Drug delivery with thermoreversible gels |
| AU662155B2 (en) * | 1991-05-10 | 1995-08-24 | Celtrix Pharmaceuticals, Inc. | Targeted delivery of bone growth factors |
| KR0145278B1 (ko) * | 1991-06-21 | 1998-07-15 | 브루스 엠. 에이센 | 골형성원 단백질 약제 |
| EP0551626A1 (en) * | 1991-12-19 | 1993-07-21 | LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. | Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation |
| EP0648239A4 (en) * | 1992-07-02 | 1995-09-27 | Collagen Corp | BIOCOMPATIBLE POLYMERIC CONJUGATES. |
| IL110589A0 (en) * | 1993-08-10 | 1994-11-11 | Bioph Biotech Entw Pharm Gmbh | Growth/differentiation factor of the TGF- beta family |
| JP3696265B2 (ja) * | 1994-02-04 | 2005-09-14 | 日本オルガノン株式会社 | 点鼻液剤 |
| DE4423396C2 (de) | 1994-07-04 | 2001-10-25 | Fraunhofer Ges Forschung | Verfahren zum Herstellen einer mikromechanischen Oberflächenstruktur |
| WO1996021427A1 (en) * | 1995-01-09 | 1996-07-18 | Atrix Laboratories, Inc. | Liquid polymer delivery system |
| US5902785A (en) * | 1995-06-06 | 1999-05-11 | Genetics Institute, Inc. | Cartilage induction by bone morphogenetic proteins |
| JPH09143093A (ja) * | 1995-11-17 | 1997-06-03 | Hoechst Japan Ltd | 軟骨・骨誘導性修復用材料 |
-
1995
- 1995-11-17 JP JP7322402A patent/JPH09143093A/ja active Pending
-
1996
- 1996-11-14 CN CNB961995645A patent/CN1165340C/zh not_active Expired - Fee Related
- 1996-11-14 AT AT96938460T patent/ATE254470T1/de active
- 1996-11-14 EP EP96938460A patent/EP0884052B1/en not_active Expired - Lifetime
- 1996-11-14 DK DK96938460T patent/DK0884052T3/da active
- 1996-11-14 UA UA98063095A patent/UA63896C2/uk unknown
- 1996-11-14 AU AU75869/96A patent/AU712445C/en not_active Ceased
- 1996-11-14 NZ NZ322188A patent/NZ322188A/xx not_active IP Right Cessation
- 1996-11-14 RU RU98111599/14A patent/RU2180234C2/ru not_active IP Right Cessation
- 1996-11-14 KR KR10-1998-0703705A patent/KR100458413B1/ko not_active IP Right Cessation
- 1996-11-14 HU HU0000411A patent/HU226201B1/hu not_active IP Right Cessation
- 1996-11-14 WO PCT/JP1996/003333 patent/WO1997018829A1/ja active IP Right Grant
- 1996-11-14 DE DE69630811T patent/DE69630811T2/de not_active Expired - Lifetime
- 1996-11-14 CA CA002235400A patent/CA2235400C/en not_active Expired - Fee Related
- 1996-11-14 US US09/068,253 patent/US6903071B2/en not_active Expired - Fee Related
- 1996-11-14 ES ES96938460T patent/ES2211993T3/es not_active Expired - Lifetime
- 1996-11-14 PT PT96938460T patent/PT884052E/pt unknown
-
1998
- 1998-05-15 NO NO19982236A patent/NO325119B1/no not_active IP Right Cessation
-
1999
- 1999-07-23 HK HK99103183A patent/HK1018205A1/xx not_active IP Right Cessation
-
2004
- 2004-07-07 US US10/885,099 patent/US7238657B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU712445C (en) | 2002-03-28 |
| EP0884052A4 (en) | 1999-05-06 |
| KR19990067676A (ko) | 1999-08-25 |
| CN1165340C (zh) | 2004-09-08 |
| CN1207047A (zh) | 1999-02-03 |
| JPH09143093A (ja) | 1997-06-03 |
| CA2235400C (en) | 2007-12-18 |
| EP0884052A1 (en) | 1998-12-16 |
| HU226201B1 (en) | 2008-06-30 |
| US20020168381A1 (en) | 2002-11-14 |
| ATE254470T1 (de) | 2003-12-15 |
| ES2211993T3 (es) | 2004-07-16 |
| UA63896C2 (en) | 2004-02-16 |
| DE69630811D1 (de) | 2003-12-24 |
| AU712445B2 (en) | 1999-11-04 |
| DE69630811T2 (de) | 2004-06-17 |
| US7238657B2 (en) | 2007-07-03 |
| US6903071B2 (en) | 2005-06-07 |
| AU7586996A (en) | 1997-06-11 |
| HK1018205A1 (en) | 1999-12-17 |
| CA2235400A1 (en) | 1997-05-29 |
| US20050013864A1 (en) | 2005-01-20 |
| RU2180234C2 (ru) | 2002-03-10 |
| NZ322188A (en) | 2000-10-27 |
| WO1997018829A1 (fr) | 1997-05-29 |
| NO982236L (no) | 1998-06-26 |
| HUP0000411A3 (en) | 2005-11-28 |
| PT884052E (pt) | 2004-04-30 |
| KR100458413B1 (ko) | 2005-04-06 |
| EP0884052B1 (en) | 2003-11-19 |
| HUP0000411A2 (hu) | 2001-04-28 |
| DK0884052T3 (da) | 2004-03-29 |
| NO982236D0 (no) | 1998-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO325119B1 (no) | Brusk- og benmorfogenetisk reparasjonsmateriale, brusk- og benreparasjonsmiddel og anvendelser derav. | |
| EP0955313B1 (en) | Novel protein and process for producing the same | |
| JP2845346B2 (ja) | 骨形成具 | |
| JP3717930B2 (ja) | Ｂｍｐ−１２、ｂｍｐ−１３およびそれらの腱誘導組成物 | |
| US6679918B1 (en) | Implantable putty material | |
| JP2002507437A (ja) | 組織の増強及び回復のための注射可能インプラント | |
| EP1844798A1 (en) | Implantable putty material | |
| CN1160721A (zh) | 成纤维细胞生长因子-2结构类似物，其生产方法及应用 | |
| CN100448890C (zh) | 来源于mp－52蛋白质的新型蛋白质及其制备方法和用途 | |
| KR100490817B1 (ko) | 119아미노산으로구성된mp52유래의단백질및그제법 | |
| CN117618668A (zh) | 一种基于胶原蛋白和软骨形成蛋白的融合蛋白的水凝胶的制备方法及应用 | |
| JP2997549B2 (ja) | 新規なタンパク質およびその製法 | |
| MXPA97008011A (en) | New protein and process for your preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |